All In Biotech

Drug Trial Radar · NCT03819296

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Role of Microbiome in the Realm of Immune-Checkpoint Inhibitor Induced GI Complications In Cancer Population

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Feb 21, 2021

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jan 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of the intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on cells, and help doctors understand how well patients respond to treatment. Treatment with fecal transplantation may help to improve diarrhea and colitis symptoms.

Conditions

  • Clinical Stage 0 Cutaneous Melanoma AJCC v8
  • Clinical Stage I Cutaneous Melanoma AJCC v8
  • Clinical Stage IA Cutaneous Melanoma AJCC v8
  • Clinical Stage IB Cutaneous Melanoma AJCC v8
  • Clinical Stage II Cutaneous Melanoma AJCC v8
  • Clinical Stage IIA Cutaneous Melanoma AJCC v8
  • Clinical Stage IIB Cutaneous Melanoma AJCC v8
  • Clinical Stage IIC Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Colitis
  • Lung Non-Small Cell Carcinoma
  • Malignant Genitourinary System Neoplasm
  • Malignant Solid Neoplasm
  • Pathologic Stage 0 Cutaneous Melanoma AJCC v8
  • Pathologic Stage I Cutaneous Melanoma AJCC v8
  • Pathologic Stage IA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IB Cutaneous Melanoma AJCC v8
  • Pathologic Stage II Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Pathologic Stage IV Cutaneous Melanoma AJCC v8
  • Stage 0 Lung Cancer AJCC v8
  • Stage I Lung Cancer AJCC v8
  • Stage IA1 Lung Cancer AJCC v8
  • Stage IA2 Lung Cancer AJCC v8
  • Stage IA3 Lung Cancer AJCC v8
  • Stage IB Lung Cancer AJCC v8
  • Stage II Lung Cancer AJCC v8
  • Stage IIA Lung Cancer AJCC v8
  • Stage IIB Lung Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IIIC Lung Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8

Interventions

  • Best PracticeOther

    Receive standard of care

  • Biospecimen CollectionOther

    Undergo collection of stool, blood, and tissue samples

  • Endoscopic ProcedureProcedure

    Undergo endoscopy

  • Fecal Microbiota TransplantationProcedure

    Undergo FMT

  • InfliximabBiological

    Given intravenously (IV)

  • Laboratory Biomarker AnalysisOther

    Ancillary studies

  • PrednisoneDrug

    Given orally

  • VedolizumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in stool microbiome patternTime frame: Up to 1 year
  2. Incidence of adverse events (AE) of fecal microbiota transplantation (FMT) (Project 3)Time frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M D Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.